Professor Terry Jones BSc (Hons), FRCSEd, FRCS (ORL-NHS), MD, SFHEA, FASE(RCS), FAcadTM

Director, Liverpool Head and Neck Centre, Professor of Head and Neck Surgery Molecular & Clinical Cancer Medicine

Research

Research Overview

My research interests may be divided into 4 main themes

1. Basic/translational research: which focusses of the differential treatment response seen between Human papillomavirus +ve and –ve oropharyngeal squamous cell carcinomas.

2. Early and late phase Clinical Trials: Joint Chief Investigator respectively for three CRUK funded H&N studies: PATHOS, PATHOS-T & EORTC 1420

3. Clinical outcomes research: with a particular interest in swallowing and voice outcomes following transoral laser microsurgery

4. Cancer Inequalities: and their impact on incidence and outcome for patients with head and neck cancer

Research Interest 1

My main clinical interests relate to function-sparing transoral laser techniques to remove cancers of the larynx (voice-box), oropharynx and hypopharynx (throat), thereby leaving patients with better speech and swallowing function after surgery.
My research interests can be divided into 3 main themes:

Basic/translational research: Much of this research is conducted in collaboration with Dr Mark Boyd, Reader in Molecular Oncology and focuses on the role of the p53 /MDM2/MTBP pathway in the development of metastasis and radioresistance and the therapeutic exploitation of the Unfolded Protein Response.

Clinical Trials: I am the Chief Investigator for the following LCTU managed trials.
REALISTIC: a CR-UK funded Phase I, dose escalation trial of recombinant Listeria monocytogenes (lm)-based vaccine encoding human papilloma virus serotype 16 target antigens (adxs11-001) in patients with Human Papilloma Virus 16 (HPV-16) associated oropharyngeal squamous cell carcinoma (OPSCC).
HPVUK: A GSK funded multi-centre study designed to establish the prevalence of HPV-16 associated OPSCC in the United Kingdom over the last decade. I am also the Principal Investigator (PI) for
TITAN: A CR-UK funded, multi-centre phase III feasibility study of induction chemotherapy in advanced Head & Neck Cancer. In addition, I am the PI for a further four ongoing multi-centre randomised clinical trials.(PET-NECK,DETERMINE, DETEQT & IoN)

Clinical outcomes research:
This inculudes the acoustic analysis of voice following TOLS for tumours of the larynx; the predictive role of cardio-pulmonary testing in patients undergoing major surgery for H&N cancer and the role of percutaneous tracheostomy in the development of adult tracheal stenosis.

Research Grants

Bench Fees Ms Alrusayyis

KING SAUD UNIVERSITY (SAUDI ARABIA)

December 2017 - November 2020

Circulating Biomarkers in Head and Neck Cancer

ROYAL COLLEGE OF SURGEONS OF ENGLAND(UK)

August 2017 - August 2018

Realizing the radiobiological impact of protons and high-LET particles in head and neck cancer and glioblastoma models

NATIONAL INSTITUTES OF HEALTH (USA)

July 2021 - April 2026

Pathos-T: A Bioresource Collection associated with PATHOS, a Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer

CANCER RESEARCH UK (UK), NORTH WEST CANCER RESEARCH INCORPORATING CLATTERBRIDGE CANCER RESEARCH (UK)

November 2015 - December 2025

PentoxIfylline and Tocopherol for the treatment of poST radiotherapy fibrOsis in head and neck cancer Patients: a feasibility study (PIT-STOP)

DEPARTMENT OF HEALTH & SOCIAL CARE (UK)

December 2017 - September 2020

Functional investigation of novel biomarkers in head and neck cancers

CANCER RESEARCH UK (UK)

September 2011 - August 2013

TITAN: Trial of induction TPF therapy in advance head and neck cancer

CANCER RESEARCH UK (UK)

October 2010 - September 2013

IMCAT - Immunotherapy for squamous cell carcinoma of the head and neck by Transimmunization

CANCER RESEARCH UK (UK)

March 2010 - November 2011

Evaluation of Metastasis-inducing Proteins as Biomarkers of Patient Outcome in Human Cancers

MEDICAL RESEARCH COUNCIL

September 2009 - February 2013

Workshop on the design and analysis of clinical trials in Head and Neck Cancer

MEDICAL RESEARCH COUNCIL

June 2013 - April 2014

Study on tumours of the oropharynx caused by the HPB virus

WARRINGTON AND HALTON HOSPITALS NHS FOUNDATION TRUSTS (UK)

July 2013 - December 2014

REALISTIC: A Phase I, dose escalation of trial of recombinant listeria moncytogenes (Lm) based vaccine encloding human papilloma virus serotype 16 target antigens (ADXS11-001) in patients with HPV-16+ oropharyngeal SCC.

CANCER RESEARCH UK (UK)

October 2010 - September 2014

Research Collaborations

Professor Tony Ng

External: King's College London

Dr Lakis Liloglou

Internal

H&N basic research rpojects

Dr Janet Risk

Internal

Dr Jacqueline James

External: The University of Ulster

UK HPV Prevalence in OPSCC Study.

Dr Liz Junor

External: The University of Edinburgh

UK HPV Prevalence in OPSCC Study. Phase III RCT of induction TPF in patients with advanced SCCHN.

Dr Stephen Man

External: University of Wales, Cardiff

Phase I trail of HPV therapeutic vaccine in patients with HPV positive Oropharyngeal Squamous Cell carcinoma. TILS in SCCHN

Professor Alison Fiander

External: The University of Wales, Cardiff

Phase I trail of HPV therapeutic vaccine in patients with HPV positive Oropharyngeal Squamous Cell carcinoma. UK HPV Prevalence in OPSCC Study.

Dr Chris Nutting

External: Institute of Cancer Research

Phase I trail of HPV therapeutic vaccine in patients with HPV positive Oropharyngeal Squamous Cell carcinoma. UK HPV Prevalence in OPSCC Study. Phase III RCT of induction TPF in patients with advanced SCCHN.

Dr Mererid Evans

External: University of Wales, Cardiff

Phase I trail of HPV therapeutic vaccine in patients with HPV positive Oropharyngeal Squamous Cell carcinoma. UK HPV Prevalence in OPSCC Study. Phase III RCT of induction TPF in patients with advanced SCCHN.

Professor Ross Sibson

Internal

Exon array analysis of SCCHN cell lines with a view to identifying differential expressed genes associated with increased cellular motility

Dr Kevin Harrington

External: Institute of Cancer Research

Phase I trail of HPV therapeutic vaccine in patients with HPV positive Oropharyngeal Squamous Cell carcinoma. UK HPV Prevalence in OPSCC Study. Phase III RCT of induction TPF in patients with advanced SCCHN.

Professor Hisham Mehanna

External: The University of Warwick

UK HPV Prevalence in OPSCC Study. Phase III RCT of induction TPF in patients with advanced SCCHN.

Dr Ned Powell

External: University of Wales, Cardiff

Phase I trail of HPV therapeutic vaccine in patients with HPV positive Oropharyngeal Squamous Cell carcinoma. UK HPV Prevalence in OPSCC Study.

Mr Richard Shaw

Internal

Ongoing collaboration to develop a strong academic department of H+N cancer medicine

Professor Kevin Park

Internal

Proteomics of H+N cancer.
Investigation of novel cytotoxic agents for HNSCC.

Dr Neil Kitteringham

Internal

The role of novel therapeutic agents in the treatment of HNSCC.
Proteomic analysis of HNSCC, in an attempt to identify biomarkers of metastatic potential.

Professor Phillip Rudland

Internal

Identification of genes involved in metastasis of HNSCC

Mr. Jean-Pierre Jeannon

External: Guys and St Thomas` NHS Trust

Randomised controlled trail of the effectiveness of Immune-enhanced feed for patients undergoing major head and neck surgery

Dr Ged Dempsey and Professor Peter Calverley

External: Aintree University Hospitals NHS Foundation Trust

The role of pre-operative Anaerobic Threshold measurement in patients undergoing major head and neck surgery

Dr Huw Lewis-Jones and Dr Rebecca Hanlon

External: Aintree University Hospitals NHS Foundation Trust

The role of CT and MR imaging in patients with head and neck cancer

Dr Jon Sheard

External: Aintree University Hospitals NHS Foundation Trust

The role of fine-needle aspiration cytology (FNAC)in the diagnosis of patients with SCCHN.

Professor Paul Carding

External: The University of Newcastle-upon-Tyne

The analysis of voice in patients with head and neck cancer,uncergoing voice-altering treatments.

Mr Simon Rogers

External: Aintree University Hospitals NHS Foundation Trust

Quality of Life outcomes in Head and Neck Cancer patients

Dr Tim Helliwell

Internal

The role of matrix metalloproteases in the development of metastasis of squamous cell carcinoma of the head and neck (SCCHN)

Dr Mark Boyd

Internal

The role of the MDM2/p53 pathway in squamous cell carcinoma of the head and neck (SCCHN)

Professor Andrew Jones

Internal

Clinical outcomes in patients with head and neck cancer.